Abstract 252P
Background
Uterine sarcomas (US) are a rare, heterogeneous group of malignancies that have rapid progressive clinical course and poor prognosis. We are reporting a retrospective review of clinico-pathological characteristics and outcome of therapy of these tumors in Qatar.
Methods
Retrospective records of 37 patients with US treated in Qatar between January 2010 and December 2016 were reviewed. They were stratified according to the age at diagnosis, menopausal status, ethnic group, pathological subtype of the tumor, grade, stage and treatment modalities (single vs combined modalities; surgical procedure, radiotherapy treatment, adjuvant and palliative chemotherapy. Diagnostic and pathology work was done in one facility. Treatment plan was discussed in MDT. The surgical treatment options were TAH with our without BSO. The chemotherapy we used is Docetaxel Gemcitabine in adjuvant setting as well as palliative treatment for metastatic cases. Radiotherapy was conducted via external beam irradiation followed by brachytherapy. Overall survival (OS) was obtained from the date of diagnosis to the date of death. For the patients who were alive, data was censored on the date of last follow up visit.
Results
For the reviewed 37 patients, the range of age was 23-64 years old with median age 47 years. LMS are representing the most frequent subtype seen in 15 patients (40%), ESS- 10 (28%), RMS 6 (16%), MMMT 2 (4 %) and non-specified 4 (12%). The stage of the disease at time of diagnosis was 1 in 26%, stage II in 48%, stage III in 11% and stage IV 15%. Total 23 patients underwent surgical resection, 12 patients (53%) simple hysterectomy and 11 (47%) TAH+BSO with LN dissection. 13 patients receivedchemotherapy, in 7 cases as adjuvant, in 4 combined with radiotherapy and in 2 cases as palliative. 13 patient received radiotherapy and brachytherapy. Median follow up time was 42 months. Thorough the time 10 patients died, 18 are still alive and 9 have lost follow up. The Kaplan Maier Curve showed median OS 40 months. Survival rate after one year was 79% and after 3 years 58%.
Conclusions
In this pattern of population where the majority of US presented in early stages (74%), 42% will die within the first 3 years which reflect the need for running big phase 3 trials for optimization of the treatment approaches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ashraf Fadlelseid.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract
238P - Laparoscopic cytoreduction in low disease burden, advanced-stage ovarian cancers: Experience from a tertiary cancer center
Presenter: Vikas Gupta
Session: Poster display session
Resources:
Abstract
239P - Impact of counseling on patient reported sexual adjustment following chemoradiation and brachytherapy for cervical cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
240P - Morbidity and mortality of cervical cancer in the Republic of Kazakhstan
Presenter: Almagul Zhabagina
Session: Poster display session
Resources:
Abstract
241P - Impact of genomic alterations and HPV genotypes on clinical outcomes of Japanese patients with locally advanced cervical cancer
Presenter: Ikumi Kuno
Session: Poster display session
Resources:
Abstract
242P - Impact of combined interstitial and intracavitary brachytherapy in locally advanced cervical cancer: A survival and toxicity profile assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
243P - Cervical cancer screening in sub-urban area of Banten and factor associated with uptake of screening
Presenter: Prio Wibisono
Session: Poster display session
Resources:
Abstract
245P - Factors influencing adherence to cryotherapy following positive VIA result as cervical cancer prevention in Temanggung, Central Java, Indonesia
Presenter: Herindita Puspitaningtyas
Session: Poster display session
Resources:
Abstract
246P - The main of reasons of advanced stage cervical cancer in Uzbekistan
Presenter: Zakhirova Nargiza
Session: Poster display session
Resources:
Abstract
247P - Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract